Pyridium (Phenazopyridine) Use Based on GFR
Pyridium should be avoided in patients with GFR <30 mL/min/1.73 m² due to increased risk of toxicity and acute kidney injury. 1, 2
Safety Considerations by GFR Level
- GFR ≥50 mL/min/1.73 m²: Standard dosing of Pyridium is generally acceptable 3
- GFR 30-50 mL/min/1.73 m²: Use with caution; consider reduced dosing and shorter duration of treatment 2
- GFR <30 mL/min/1.73 m²: Avoid use due to increased risk of acute tubular necrosis, acute interstitial nephritis, and methemoglobinemia 1
- Dialysis patients: Contraindicated due to inability to clear the medication effectively 1
Mechanism of Renal Toxicity
- Phenazopyridine can cause direct injury to renal tubular epithelial cells 2
- May induce pigment-induced nephropathy from associated hemolytic anemia 2
- Can cause acute interstitial nephritis even at therapeutic doses 2
- Methemoglobinemia from phenazopyridine can lead to hypoxic renal injury 1
Monitoring Recommendations
- For patients with borderline renal function (GFR 30-50 mL/min/1.73 m²) who require Pyridium:
Special Considerations
- Even small overdoses (1,200 mg) have been reported to cause acute renal failure in patients without prior kidney disease 1
- Patients with HIV, diabetes, or other comorbidities may be at higher risk for nephrotoxicity even with therapeutic doses 1
- When using for diagnostic purposes (e.g., ureteral orifice identification), administer the evening before procedure rather than same day to minimize renal exposure while maintaining efficacy 3